- Eli Lilly says the Bridge program is boosting U.S. sales of its GLP-1 drugs.
Eli Lilly says the federal Bridge program, which began in July, is boosting U.S. sales of its GLP-1 drugs and is a key driver behind its raised full-year revenue guidance. CEO David Ricks said seven out of ten new Bridge patients are starting on a Lilly obesity medication.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.